logo
logo

ReViral Raises $44 Million in Series C Financing

Aug 25, 2020almost 5 years ago

Amount Raised

$44 Million

Round Type

series c

United Kingdom

Description

ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), today announced the close of a US $44 million Series C financing led by CR-CP Life Science Fund. Additional investors participating in the financing include Andera Partners, Brace Pharma Capital, Green Sands Equity, New Leaf Venture Partners, Novo Holdings, OrbiMed Advisors, and Perceptive Advisors. Jason Zhou M.D., CEO and Managing Director of CR-CP Life Science Fund, joins the ReViral Board of Directors.

Company Information

Company

Re Viral

Location

United Kingdom

About

For more information, please visit www.reviral.com

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech